PATIENTS AND METHODS

Patients
From April 1995 to October 1996, 53 subsequent patients underwent at least excisional biopsy for DCIS at the Department of Obstetrics and Gynaecology, University of Ulm. Serum of 43 patients with histologically diagnosed DCIS of the breast was available for analysis. Sera were collected preoperatively and were stored at -80°C. By routine mammography 26 patients had suspicious areas with granular microcalcifications, one patient demonstrated a suspicious dense lesion. Thirteen patients presented with a palpable breast lump and three patients complained of nipple discharge. Two patients had previously been treated for invasive breast cancer of the contralateral breast. The median age of the patients was 52 years ranging from 26 to 86 years.
Serological analysis
p53 AAb were measured in serum using a sandwich enzymelinked immunosorbent assay (ELISA) with microtitre plates coated with recombinant human p53 protein expressed in Escherichia coli (Dianova, Hamburg) . Compared to control sera supplied by the manufacturer, results were categorized as negative, low, medium and high level.
Histology
Formalin-fixed, paraffin-embedded tissue samples from all 43 patients were analysed. Nuclear grade was defined as grades 1-3 according to previously described criteria (Lagios, 1990) . The histological subtype was classified in comedo and noncomedo subtype.
Immunohistochemistry
Tumour cell staining for p53 protein was performed with the monoclonal antibody DO-1 (Dianova, Hamburg). Immunostaining for oestrogen (ER) and progesterone receptors (PR) was performed with the monoclonal antibodies ID-5 (Immunotech, Hamburg) and 1A-6 (Dako, Hamburg) respectively. For semiquantitative assessment, immunohistochemical staining for nuclear p53 of more than 10% of the tumour cells was interpreted as positive. Hormone receptor status was scored according to an immunoreactive score assessing the proportion of stained cells and the staining intensity (Remmele and Stegner, 1987 
RESULTS
p53 AAb were detected in serum of 5/43 patients (11.6%) with DCIS, three of which had lesion sizes ≤ 5 mm. p53 AAb titre was low in all five sera compared with assay control samples. The two patients previously treated for invasive breast cancer had negative test results in the ELISA. p53 AAb status with regard to clinical and histopathological parameters are presented in Table 1 . Tumour samples were evaluable for immunohistochemistry from 30/43 patients due to the small size of the tumour tissue. Expression of ER and PR was analysed in 29 and 27 patients respectively. In 23 cases of non-disseminated lesions, the size ranged from 3 to 90 mm (mean 21 mm). In the 20 patients with disseminated DCIS lesions the tumour size could not be exactly determined. Nuclear grade could be assessed in 21/43 tumours due to the heterogeneity of the tissue. Clinical presentation and histopathological data of p53 AAb-positive patients are listed in Table 2 . No association of p53 AAb status with age, clinical presentation, tumour size, grading, p53-IHC, hormone receptor status and histological subtype was observed. Only one of nine patients with comedo subtype DCIS was positive for p53 AAb with > 90% p53-positive tumour cells.
DISCUSSION
The prevalence of p53 AAb in our cohort of patients with DCIS (11.6%) was comparable to the prevalence found in invasive breast cancer which varied from 5% to 26% (Schlichtholz et al, 1992; Angelopoulou et al, 1994; Mudenda et al, 1994; Peyrat et al, 1995) . In a population-based study (n = 237) we found an overall prevalence of 16.5% in patients with invasive breast cancer using the same test system as in this study (unpublished data). In a previous study applying an ELISA technique and testing 182 newly diagnosed breast cancer patients, 8/23 (35%) patients with DCIS had p53 AAb (Mudenda et al, 1994) . Our ELISA assay was tested on 41 healthy blood donors in another study, all of which were negative for p53 AAb (Maass et al, 1996) . This demonstrates the high specificity for malignancy. The variation in the reported p53 AAb prevalences may be explained by the different techniques applied such as ELISA, immunoprecipitation or immunoblot (Angelopoulou et al, 1994; Mudenda et al, 1994; Peyrat et al, 1995) . It may also be due to different clinical stages within the study populations. Interestingly, in our study p53 AAb were detected in patients with tumour lesions of 3 mm and 5 mm. Therefore, p53 AAb immunogenicity of breast cancer cells was not associated with extended lesions. Two patients with p53 AAb had no p53 protein expression in the tumour. This observation was also made in a previous study (Mudenda et al, 1994 ) with five of 23 seropositive breast cancer patients who had no detectable p53 accumulation in the tumour. In these patients, the immunogenic reaction may have occurred earlier in tumour development or factors other than accumulation such as the type of p53 mutation or complex formation between p53 and a 70 kDa heat shock protein contributed to the p53 AAb production (Davidoff et al, 1992) . p53 AAb can already be present in patients with early, nonpalpable lesions. Given the high specificity for malignancy, the p53 AAb ELISA may become a helpful tool in the diagnostic process in subsets of DCIS patients to be defined in further studies.
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